MRKR NASDAQ
Marker Therapeutics, Inc.
1W: -8.7%
1M: -16.0%
3M: -29.1%
YTD: -31.8%
1Y: +15.6%
3Y: -77.8%
5Y: -94.1%
$1.05
+0.00 (+0.00%)
Weekly Expected Move ±7.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-04-26
Earliest Filing
2025-06-17
Latest Filing
partner: 3
supplier: 2
acquirer: 2
investor: 1
Counterparties (Filed by MRKR)
8 relationshipsCompanies named in MRKR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cellipont Bioservices | — | supplier | Marker Therapeutics entered into a Statement of Work for cGMP manufacturing and technology transfer services for MT-601. | 2025-06-17 | View |
| Cell Ready LLC | — | supplier | CDMO providing GMP drug product and quality control testing for Marker MT-401 and/or MT-601 | 2024-02-26 | View |
| Cell Ready, LLC | — | acquirer | Acquired manufacturing facilities, equipment, and supply agreements from Marker Therapeutics, Inc. | 2023-06-30 | View |
| Cell Ready, LLC | — | acquirer | Acquired manufacturing facilities, equipment, and supply agreements from Marker Therapeutics, Inc. | 2023-05-01 | View |
| Indapta Therapeutics, Inc. | — | partner | Joint party to the Master Services Agreement for Product Supply assigned to Cell Ready, LLC. | 2023-05-01 | View |
| AlloVir, Inc. | — | partner | Received development services from Marker Therapeutics, Inc. under a services agreement. | 2023-05-01 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Marker Therapeutics entered into a purchase agreement to sell up to $25,000,000 of common stock to Lincoln Park Capital | 2022-12-13 | View |
| Wilson Wolf Manufacturing Corporation | — | partner | Entered into a binding services agreement for training and manufacturing process optimization. | 2022-04-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-05-04 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-02-09 | Shareholder Nominations; Financial Statements and Exhibits | View | |
| 2025-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-05 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-10-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-12 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-06-17 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-09 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-27 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-03-04 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-02-19 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2025-01-30 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-23 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2024-12-19 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2024-12-17 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-12 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR